Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AURINIA PHARMACEUTICALS INC.

(AUPH)
  Report
Delayed Quote. Delayed Nasdaq - 11/30 04:00:01 pm
18.84 USD   +2.73%
11/22Health Care Stocks Finishing Mixed This Afternoon
MT
11/22Top Midday Decliners
MT
11/22Health Care Stocks Drifting Near Unchanged Mark Monday
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
19.36(c) 19.71(c) 19.33(c) 18.34(c) 18.84 Last
10 235 344 2 990 031 2 129 584 4 264 400 3 379 580 Volume
-1.48% +1.81% -1.93% -5.12% +2.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 45,7 M - -
Net income 2021 -181 M - -
Net cash position 2021 254 M - -
P/E ratio 2021 -13,4x
Yield 2021 -
Sales 2022 207 M - -
Net income 2022 -47,8 M - -
Net cash position 2022 220 M - -
P/E ratio 2022 -51,3x
Yield 2022 -
Capitalization 2 443 M 2 443 M -
EV / Sales 2021 48,0x
EV / Sales 2022 10,7x
Nbr of Employees 294
Free-Float 92,3%
More Financials
Company
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support... 
More about the company
Ratings of Aurinia Pharmaceuticals Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about AURINIA PHARMACEUTICALS INC.
11/22Health Care Stocks Finishing Mixed This Afternoon
MT
11/22Top Midday Decliners
MT
11/22Health Care Stocks Drifting Near Unchanged Mark Monday
MT
11/22Aurinia Pharmaceuticals Shares Sink After Filing Prospectus to Sell $250 Million Securi..
MT
11/22Wall Street Sees Upbeat Open as Potential China Easing Lifts Sentiment
MT
11/22Top Premarket Decliners
MT
11/22Aurinia Pharmaceuticals Plans $250 Million Securities Offering -- Shares Slump in Pre-M..
MT
11/10Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
BU
11/08American College of Rheumatology Convergence 2021
PU
11/08American Society of Nephrology Kidney Week 2021
PU
11/04SVB Leerink Adjusts Aurinia Pharmaceuticals' Price Target to $35 from $28, Keeps Outper..
MT
11/04HC Wainwright Adjusts Aurinia Pharmaceuticals' Price Target to $40 from $35, Keeps Buy ..
MT
11/03AURINIA PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/03Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/03Aurinia Pharmaceuticals Q3 Net Loss Widens Amid Increase in Revenue, Reaffirms 2021 Rev..
MT
More news
News in other languages on AURINIA PHARMACEUTICALS INC.
11/22Les actions du secteur de la santé terminent en demi-teinte cet après-midi
11/22Les actions du secteur de la santé dérivent près de la marque inchangée lundi
11/22Les actions d'Aurinia Pharmaceuticals chutent après le dépôt d'un prospectus pour vendr..
11/22Aurinia Pharmaceuticals propose une offre de titres d'une valeur de 250 millions de dol..
11/03La perte nette d'Aurinia Pharmaceuticals au troisième trimestre s'accentue malgré l'aug..
More news
Analyst Recommendations on AURINIA PHARMACEUTICALS INC.
More recommendations
Chart AURINIA PHARMACEUTICALS INC.
Duration : Period :
Aurinia Pharmaceuticals Inc. Technical Analysis Chart | AUPH | CA05156V1022 | MarketScreener
Technical analysis trends AURINIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 18,84 $
Average target price 32,00 $
Spread / Average Target 69,9%
EPS Revisions
Managers and Directors
Peter S. Greenleaf President, Chief Executive Officer & Director
Joseph M. Miller Chief Financial Officer
George M. Milne Chairman
Robert B. Huizinga Executive Vice President-Research
Neil Solomons Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AURINIA PHARMACEUTICALS INC.36.23%2 378
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.28.27%66 062
VERTEX PHARMACEUTICALS-19.56%48 336